#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Perspectives in Surgery / 2020 - 11

Differentiated thyroid microcarcinoma − current perspective

Czech version

Authors: J. Šafránek 1;  V. Třeška 1;  T. Skalický 1;  T. Kural 1;  P. Hošek 2
Authors‘ workplace: Chirurgická klinika, Lékařská fakulta Univerzity Karlovy v Plzni 1;  Biomedicínské centrum, Lékařská fakulta Univerzity Karlovy v Plzni 2
Published in: Rozhl. Chir., 2020, roč. 99, č. 11, s. 497-501.
Category: Original articles

Overview

Introduction: Differentiated thyroid cancer (DTC) has a good prognosis and low mortality despite its growing incidence, which is particularly the case of microcarcinomas (T1a – up to 10 mm).

Methods: Retrospective analysis of overall survival of patients in the group of thyroid gland surgeries for differentiated forms of microcarcinoma in the period of 2006–2015 up to the present. An overview of contemporary therapeutic methods is included.

Results: Thyroid cancer was detected in 144 cases out of the total of 1820 patients with thyreopathy undergoing surgery (8%); DTC microcarcinoma was detected in 65 cases (45.1%) of all carcinomas. The papillary form was diagnosed in 59 cases (51.8% of all papillary cases), and the follicular form was found in 6 cases (37.5% of all follicular cases). Two cases of Hürthle cells cancer were found, both in a stage higher than T1. Overall 10-year survival of carcinomas >T1 was 86%, reaching 90% in the microcarcinoma group (Gehan Wilcoxon test: p=0.10675).

Conclusion: Differentiated microcarcinoma shows a very good overall survival. Provided that other criteria are satisfied, particularly unifocal occurrence without spreading through the gland casing and without any suspicion of nodal involvement, hemithyroidectomy is considered to be a sufficient procedure or the method of choice, respectively.

Keywords:

thyroidectomy – lobectomy – microcarcinoma

Sources
  1. Aschebrook-Kilfoy B, Ward MH, Sabra MM, et al. Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid 2011;21:125–134. doi:10.1089/thy.2010.0021.
  2. Weber T, Peth S, Hummel R. Chirurgie papillärer Mikrokarzinome der Schilddrüse. Chirurg 2018;89(6):415−421. doi.org/10.1007/s00104-017-0571-4.
  3. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1–133. doi:10.1089/thy.2015.0020.
  4. Šafránek J, Třeška V, Skalický T, et al. Karcinom štítné žlázy, desetiletý soubor. Rozhl Chir. 2016;95:394–397.
  5. Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol. (Oxf) 1977;7:481–493. doi:10.1111/j.1365-2265.1977.tb01340.x.
  6. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med. 1997;126:226–231. doi:10.7326/0003-4819-126-3-199702010-00009.
  7. Guth S, Theune U, Aberle J, et al. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest. 2009;39:699–706. doi:10.1111/j.1365-2362.2009.02162.x.
  8. Brito JP, Al Nofal A, Montori V, et al. The impact of subclinical disease and mechanism of detection on the rise in thyroid cancer incidence: a population-based study in Olmsted County, Minnesota during 1935 through 2012. Thyroid 2015;25:999–1007. doi:10.1089/thy.2014.0594.
  9. Vlček P. Diferencovaný karcinom štítné žlázy – nový pohled na jeho léčbu. Onkologie 2011;5(6):329–332.
  10. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109–142. doi:10.1089/thy.2006.16.ft-1.
  11. Vlček P, Nováková D, Vejvalka J, et al. Návrh optimálního léčebného postupu v léčbě nízkorizikového karcinomu štítné žlázy. Vnitř Lék. 2015;61(9):769−777.
  12. Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375–381. doi:10.1097/SLA.0b013e31814697d9.
  13. Barney BM, Hitchcock YJ, Sharma P, et al. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck 2011;33:645–649. doi:10.1002/hed.21504.
  14. Nixon IJ, Ganly I, Patel SG, et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery 2012;151:571–579. doi:10.1016/j.surg.2011.08.016.
  15. Grant CS, Hay ID, Gough IR, et al. Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery 1988;104:954–962.
  16. Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998;124:958–964.
  17. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447–1463. doi:10.1210/jcem.86.4.7407.
  18. Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) 2012; 91:274–286. doi:10.1097/MD.0b013e31826a9c71.
  19. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAFV600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013;309:1493–1501. doi:10.1001/jama.2013.3190.
  20. Bishop JA. Pitfalls in the surgical pathologic diagnosis of papillary thyroid carcinoma. Diagnostic Histopathology 2016;22(5):191–198.
  21. Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996;5:43–63.
  22. Scheumann GF, Gimm O, Wegener G, et al. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg. 1994;18:559–567. doi:10.1007/bf00353765.
  23. Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003;13:381–387. doi:10.1089/105072503321669875.
  24. Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasono­graphy in the surgical management of patients with thyroid cancer. Surgery 2003;134:946–954. doi:10.1016/s0039-6060(03)00424-0.
  25. Hughes DT, White ML, Miller BS, et al. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery 2010; 148:1100–1106. doi:10.1016/j.surg.2010.09.019.
  26. Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 2012;22:1144–1152. doi:10.1089/thy.2012.0043.
  27. Lang BH, Wong KP, Wan KY, et al. Impact of routine unilateral central neck dissection on preablative and postablative stimulated thyroglobulin levels after total thyroidectomy in papillary thyroid carcinoma. Ann Surg Oncol. 2012;19:60–67. doi:10.1245/s10434-011-1833-x.
  28. Wang TS, Evans DB, Fareau GG, et al. Effect of prophylactic central compartment neck dissection on serum thyroglobulin and recommendations for adjuvant radioactive iodine in patients with differentiated thyroid cancer. Ann Surg Oncol. 2012;19:4217–4222. doi:10.1245/s10434-012-2594-x. 
  29. Carty SE, Cooper DS, Doherty GM, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 2009;19:1153–1158. doi:10.1089/thy.2009.0159.
  30. Popadich A, Levin O, Lee JC, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery 2011;150:1048–1057. doi:10.1016/j.surg.2011.09.003.
  31. Sywak M, Cornford L, Roach P, et al. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery 2006;140:1000–1005. doi:10.1016/j.surg.2006.08.001.
  32. Matsuzu K, Sugino K, Masudo K, et al Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014;38:68C79. doi:10.1007/s00268-013-2224-1.
  33. Dvořák J. Chirurgická anatomie a technika operací štítné žlázy. Praha 1995:168–170.
  34. Carling T, Carty SE, Ciarleglio MM, et al. American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid 2012;22:237V244. doi:10.1089/thy.2011.0317.
Labels
Surgery Orthopaedics Trauma surgery
History of thyroid surgery
What should a surgeon known about genetic background of thyroid cancer
Papillary thyroid microcarcinoma and papillary thyreoid cancer at the Department of Surgery, EUC Clinic Zlín
Retrosternal goiter
Chirurgie štítné žlázy a příštítných tělísek
Harmonic scalpel versus traditional ligation in axillary dissection for breast cancer: a retrospective multivariate analysis
Endoscopic approaches in head and neck endocrine surgery − introduction of TOETVA (TransOral Endoscopic Thyroidectomy by Vestibular Approach) into clinical use at the Department of Surgery of the University Hospital in Brno
Zakladatel německé neurochirurgie a prvního samostatného neurochirurgického časopisu Wilhelm Tönnis (1898–1978) – dílo v kontextu doby
Article was published in

Perspectives in Surgery

Issue 11
2020 Issue 11
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#